Recent research have focused on the intersection of glucagon-like peptide-1|GIP|GCGR stimulant therapies and dopaminergic neurotransmission. While GCGR stimulators are commonly employed for addressing type 2 diabetes, their unexpected effects on motivation circuits, specifically mediated by dopamine pathways, are attracting considerable attention.